Perspectives from the antihypertensive and lipid-lowering treatment to prevent heart attack trial - Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm

Current Opinion in Lipidology

Volumn 14, Issue 6, 2003, Pages 593-597

  Brown, William Virgil ^a   Moussa, Mohamad ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Coronary heart disease; High blood pressure; LDL; Low density lipoprotein; Statin; Stroke

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

CLINICAL TRIAL; COMPARATIVE STUDY; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; METHODOLOGY; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 9644292460     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200312000-00007     Document Type: Review

References (20)

1. Sacks FM, Tonkin AM, Shepherd J, et al. for the Prospective Pravastatin Pooling Project. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation 2000; 102:1893-1900.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet 2002; 360:7-22
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
4. ASCOT investigators group. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentration in ASCOT-LLA: a multicentre randomized controlled trial. Lancet 2003; 361:1149-1158.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with Isolated Systolic Hypertension (SHEP). JAMA 1991; 265:3255-3264.
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, II: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-838.
7. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
8. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction In patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
9. Crouse JR III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998; 138:11-24.
10. Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analaysis of randomized trials. Arch Intern Med 2003; 163:669-676.
11. Davis BR, Cutler JA, Gordon DJ, et al. for the ALLHAT Research Group. Rationale and design for the Antihypertensive and lipid Lowering Treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360.
12. Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT. http://www.ascotstudy. co.uk [Accessed 14 March 2003]
13. Lipid Research Clinic Program. The Lipid Research Clinic Coronary Primary Prevention Trial results: I Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
14. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
15. Auer J, Berent R, Weber T, Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 2002; 9:1831-1850.
16. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97:105-116.
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
18. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
19. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
20. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.